Therefore, we hypothesize that SMAD2 plays a critical role in regulating the expression and activity of DNMT1, the upregulation of which leads to CLND6 promoter hypermethylation and downregulation of CLDN6 expression, which promote EMT and enhancesmigration and invasion ability of breast cancer cells. Here, CLDN6 is linked to breast cancer.